Yahoo · Oct 7, 2026
Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.
NASDAQ · MRK
Merck & Co., Inc.
Healthcare · Drug Manufacturers - General
$141.94
Up+$0.85 (+0.60%)
Updated Oct 7, 2026, 9:42 PM
SID Score
8.3/10
Composite research score
Smart Money
61/100
Neutral
- Market cap
- 248.84B
- P/E ratio
- 12.99
- Dividend yield
- 2.88%
- 52-week range
- $104.33 – $156.92
- Volume
- 8.07M
- Avg. volume
- 13.42M
Price performance · MRK
MRK price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MRK closed at $141.94 after 21 trading sessions, down 4.39% for the selected period.
- Last close
- $141.94
- Period change
- -4.39%
- Period low
- $139.54
- Period high
- $150.91
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $140.13 | $142.16 | $139.74 | $141.94 | 8.07M |
| Oct 5, 2026 | $143.67 | $144.06 | $138.80 | $139.54 | 9.49M |
| Oct 2, 2026 | $143.77 | $144.35 | $142.73 | $144.30 | 9.66M |
| Oct 1, 2026 | $144.71 | $145.388 | $143.26 | $143.81 | 7.86M |
| Sep 30, 2026 | $148.945 | $149.27 | $145.26 | $145.31 | 10.23M |
| Sep 29, 2026 | $148.17 | $150.36 | $146.0879 | $149.28 | 8.2M |
| Sep 28, 2026 | $147.65 | $149.19 | $146.28 | $148.69 | 7.7M |
| Sep 25, 2026 | $148.06 | $149.98 | $147.48 | $148.78 | 8.29M |
| Sep 24, 2026 | $148.165 | $151.46 | $147.90 | $147.98 | 10.31M |
| Sep 23, 2026 | $151.315 | $152.01 | $146.89 | $148.08 | 9.7M |
| Sep 22, 2026 | $148.69 | $153.57 | $148.04 | $150.91 | 11.17M |
| Sep 21, 2026 | $146.785 | $150.49 | $145.60 | $149.50 | 8M |
| Sep 18, 2026 | $147.08 | $147.84 | $145.74 | $146.87 | 31.16M |
| Sep 17, 2026 | $145.74 | $147.65 | $145.323 | $147.15 | 11.06M |
| Sep 16, 2026 | $143.96 | $144.97 | $143.50 | $144.91 | 7.23M |
| Sep 15, 2026 | $143.85 | $144.15 | $142.32 | $143.79 | 8.29M |
| Sep 14, 2026 | $146.42 | $147.09 | $144.10 | $144.85 | 7.41M |
| Sep 11, 2026 | $145.52 | $145.90 | $143.68 | $143.93 | 8.68M |
| Sep 10, 2026 | $147.94 | $148.00 | $144.10 | $144.71 | 7.54M |
| Sep 9, 2026 | $148.96 | $149.41 | $147.18 | $147.53 | 8.55M |
| Sep 8, 2026 | $148.41 | $149.60 | $146.281 | $148.46 | 11.19M |
Latest MRK news
The latest Smart Investors Daily articles mentioning MRK.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MRK research
Overview
Company profile and research snapshot.
Company profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $112.00
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | JP Morgan | Overweight | — |
| Sep 29, 2026 | Scotiabank | Sector Outperform | — |
| Sep 10, 2026 | HSBC | Buy | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 8, 2026 | Guggenheim | Buy | — |
News briefing
Generated Oct 7, 2026, 7:06 PM
Why Is MRK Up Today? Strategic Partnerships and Market Resilience Drive Gains
Merck shares rose 0.75% today as the pharmaceutical giant demonstrated resilience amid broader biotech sector volatility. The uptick reflects investor confidence in MRK's strategic positioning, highlighted by a multi-year collaboration announcement with Tempus and Moderna, while the company continues to outperform broader market dynamics.
Bottom line: Merck's modest 0.75% gain reflects steady investor confidence driven by strategic partnerships and relative sector outperformance, though the company faces mounting competitive pressures in key vaccine markets from emerging players. Investors should monitor the Tempus collaboration's development progress while watching for competitive threats to MRK's vaccine franchise from newer entrants like Vaxcyte. The stock's dividend appeal and diversified portfolio provide downside protection, making it a relatively defensive pharma holding in an increasingly volatile biotech environment.
Yahoo · Oct 7, 2026
Halozyme stock rises after winning injunction against Merck
Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets.
Yahoo · Oct 7, 2026
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.
Yahoo · Oct 7, 2026
Tempus Announces Multi-Year Collaboration with Moderna and Merck
CHICAGO, October 07, 2026--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know
AI research layers
Interpretive context generated from the platform’s current data sources.
Merck & Co. Stock Performance
Merck & Co. shares closed at $141.93, reflecting a single-session decline of approximately 2.49% per SID market data. Over the trailing one-month period, MRK has retreated by 5.58%, though the stock maintains a solid three-month gain of 12.66% and a robust one-year appreciation of 35.54%. The current price sits just below the 50-day moving average of $142.68, suggesting the stock is testing a near-term technical support level, while remaining well above the 200-day moving average of $124.96. The 14-day relative strength index registers at 43.8, placing the stock in neutral territory but tilting toward oversold conditions. According to Massive/Polygon data, average daily trading volume stands at approximately 13.42 million shares. Merck's beta of 0.299 indicates significantly lower volatility than the broader market, consistent with its positioning within the defensive healthcare sector and its large-cap market capitalization of approximately $248.8 billion.
Merck & Co. Valuation Analysis
Merck & Co. trades at a trailing price-to-earnings ratio of approximately 12.99, which positions the company at a notable discount relative to the broader S&P 500 and many healthcare sector peers, per SID market data. The PEG ratio stands at 0.79, falling below the commonly referenced fair-value threshold of 1.0, which suggests the stock's earnings growth rate may not be fully reflected in its current valuation. According to SEC filings, Merck offers a dividend yield of approximately 3.27%, providing meaningful income for shareholders and reinforcing its appeal as a defensive holding. The price-to-book ratio of 4.77 reflects the premium typically associated with pharmaceutical companies that hold significant intangible assets, including patents and pipeline intellectual property. Taken together, these metrics indicate that Merck's valuation remains compressed relative to its growth profile, with the sub-1.0 PEG ratio and double-digit P/E representing key data points for fundamental analysis.
Smart Money Activity for MRK
Merck & Co. registers a composite smart money score of 61 out of 100, generating a neutral overall signal according to SID market data. Institutional ownership activity scores a perfect 25 out of 25, reflecting strong conviction among large asset managers and fund complexes. Congressional trading activity also registers elevated interest at 15.6 out of 25. However, insider activity presents a more cautious picture, scoring 12.0 out of 25. According to SEC Form 4 filings, there have been 20 insider transactions over the past 90 days, with sells outnumbering buys at a ratio of three to one — specifically, 15 insider sales compared to only 5 insider purchases. Dark pool activity scores a modest 8.5 out of 25, suggesting relatively limited off-exchange block trading interest in recent weeks. The divergence between robust institutional positioning and the insider selling pattern creates a mixed signal landscape. Per 13F institutional filings, the strong institutional score confirms that major fund managers continue to maintain or increase their positions despite the insider selling activity observed during the quarter.
Merck & Co. Earnings Outlook
Merck & Co.'s most recent reported quarter showed an adjusted loss of $1.28 per share, which nonetheless exceeded analyst expectations of a $1.48 loss, delivering a positive earnings surprise of $0.20 per share according to company earnings reports. The subsequent quarter posted a loss of $0.13 per share against a consensus estimate of $0.23 in earnings, representing a negative surprise of $0.36. Looking ahead, analyst estimates project Merck to report earnings of $0.30 per share for the upcoming quarter and $2.19 per share for the following period, per consensus data. The trajectory from negative earnings in earlier quarters toward substantially positive estimates of $2.19 suggests analysts anticipate a meaningful recovery in profitability. The sequential improvement in estimates reflects expectations around Merck's key revenue drivers, including its oncology and vaccine portfolios. Investors will closely monitor whether the company can sustain the projected earnings recovery trajectory in forthcoming reports.
Wall Street Analyst Ratings for MRK
Wall Street consensus on Merck & Co. remains uniformly positive, with all five most recent analyst actions reiterating bullish ratings according to SID consensus data. On October 5, JP Morgan maintained its Overweight rating on MRK, while Scotiabank reiterated a Sector Outperform designation on September 29. HSBC reaffirmed its Buy rating on September 10, followed by Leerink Partners maintaining Outperform on September 9 and Guggenheim sustaining its Buy recommendation on September 8. Notably, none of the five recent analyst updates involved a downgrade or a change in directional stance, indicating sustained conviction across multiple research desks. Per Wall Street analyst reports, the consistency of these ratings across diverse firms — spanning global banks, regional brokerages, and specialized healthcare research platforms — underscores broad institutional agreement on Merck's fundamental outlook. The lack of any neutral or negative revisions during this period is particularly notable given the stock's 5.58% pullback over the trailing one-month period, suggesting analysts view the recent weakness as temporary.
